Evidence map›Paper›PMID 31449469›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

Phase II Study of Proton Beam Radiation Therapy for Patients With Breast Cancer Requiring Regional Nodal Irradiation.

Rachel B Jimenez, Shea Hickey, Nicolas DePauw, Beow Y Yeap, Estelle Batin, Michelle A Gadd, Michelle Specht, Steven J Isakoff, Barbara L Smith, Eric C Liao and 8 more

Open access · bronzeAbstract readClinical Trial, Phase II
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 104 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 5 countries.

Rachel B JimenezMassachusetts General Hospital, Boston, MA.
Shea HickeyMassachusetts General Hospital, Boston, MA.
Nicolas DePauwMassachusetts General Hospital, Boston, MA.
Beow Y YeapMassachusetts General Hospital, Boston, MA.
Estelle BatinMassachusetts General Hospital, Boston, MA.
Michelle A GaddMassachusetts General Hospital, Boston, MA.
Michelle SpechtMassachusetts General Hospital, Boston, MA.
Steven J IsakoffMassachusetts General Hospital, Boston, MA.
Barbara L SmithMassachusetts General Hospital, Boston, MA.
Eric C LiaoMassachusetts General Hospital, Boston, MA.
Amy S ColwellMassachusetts General Hospital, Boston, MA.
Alice HoMassachusetts General Hospital, Boston, MA.
James L JanuzziMassachusetts General Hospital, Boston, MA.
Jonathan PasseriMassachusetts General Hospital, Boston, MA.
Tomas G NeilanMassachusetts General Hospital, Boston, MA.
Alphonse G TaghianMassachusetts General Hospital, Boston, MA.
Hsiao-Ming LuMassachusetts General Hospital, Boston, MA.
Shannon M MacDonaldMassachusetts General Hospital, Boston, MA.
Abbott (Germany) · DEMyriad (Germany) · DEAstraZeneca (Poland) · PLImmunomedics (Germany) · DEMerck (Germany) · DEPuma Biotechnology (United States) · USAbbVie (United States) · USMassachusetts General Hospital · USRoche (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the safety and efficacy of proton beam radiation therapy (RT) for patients with breast cancer who require regional nodal irradiation.

methodsPatients with nonmetastatic breast cancer who required postoperative RT to the breast/chest wall and regional lymphatics and who were considered suboptimal candidates for conventional RT were eligible. The primary end point was the incidence of grade 3 or higher radiation pneumonitis (RP) or any grade 4 toxicity within 3 months of RT. Secondary end points were 5-year locoregional failure, overall survival, and acute and late toxicities per Common Terminology Criteria for Adverse Events (version 4.0). Strain echocardiography and cardiac biomarkers were obtained before and after RT to assess early cardiac changes.

resultsSeventy patients completed RT between 2011 and 2016. Median follow-up was 55 months (range, 17 to 82 months). Of 69 evaluable patients, median age was 45 years (range, 24 to 70 years). Sixty-three patients (91%) had left-sided breast cancer, two had bilateral breast cancer, and five had right-sided breast cancer. Sixty-five (94%) had stage II to III breast cancer. Sixty-eight (99%) received systemic chemotherapy. Fifty (72%) underwent immediate reconstruction. Median dose to the chest wall/breast was 49.7 Gy (relative biological effectiveness) and to the internal mammary nodes, 48.8 Gy (relative biological effectiveness), which indicates comprehensive coverage. Among 62 surviving patients, the 5-year rates for locoregional failure and overall survival were 1.5% and 91%, respectively. One patient developed grade 2 RP, and none developed grade 3 RP. No grade 4 toxicities occurred. The unplanned surgical re-intervention rate at 5 years was 33%. No significant changes in echocardiography or cardiac biomarkers after RT were found.

conclusionProton beam RT for breast cancer has low toxicity rates and similar rates of disease control compared with historical data of conventional RT. No early cardiac changes were observed, which paves the way for randomized studies to compare proton beam RT with standard RT.

Indexed as

AdultAgedBreast NeoplasmsFemaleHumansLymph NodesMiddle AgedProton TherapyRadiotherapy DosageYoung Adult

Identifiers

PMID31449469
PMCPMC7351324
OpenAlexW2971295976

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.